Cabozantinib in patients with advanced and progressing hepatocellular carcinoma Academic Article uri icon

Overview

MeSH Major

  • Anilides
  • Antineoplastic Agents
  • Carcinoma, Hepatocellular
  • Liver Neoplasms
  • Pyridines
  • Receptor Protein-Tyrosine Kinases

abstract

  • Among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression-free survival than placebo. The rate of high-grade adverse events in the cabozantinib group was approximately twice that observed in the placebo group. (Funded by Exelixis; CELESTIAL ClinicalTrials.gov number, NCT01908426 .).

publication date

  • July 5, 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1717002

PubMed ID

  • 29972759

Additional Document Info

start page

  • 54

end page

  • 63

volume

  • 379

number

  • 1